Shaperon（A378800）株式概要臨床段階のバイオテクノロジー企業であるシャペロン社は、アンメット・メディカル・ニーズの高い免疫介在性炎症性疾患を標的とした新規のインフラマソーム阻害剤とナノボディ治療薬を開発している。 詳細A378800 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( ₩281M )KR市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去5年間で収益は年間8.7%減少しました。 過去1年間で株主の希薄化は大幅に進んだ +1 さらなるリスクすべてのリスクチェックを見るA378800 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW502,015 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG502,015 investors already sharing narrativesYour Fair Value₩Current Price₩503.009.0k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-16b1b2016201920222025202620282031Revenue ₩281.4mEarnings ₩52.0mAdvancedSet Fair ValueView all narrativesShaperon Inc. 競合他社GenesystemSymbol: KOSDAQ:A363250Market cap: ₩28.3bPoongjeon PharmacyLTDSymbol: KOSDAQ:A298060Market cap: ₩23.8bQuratisSymbol: KOSDAQ:A348080Market cap: ₩32.6bDaesung Microbiological LabsSymbol: KOSDAQ:A036480Market cap: ₩22.1b価格と性能株価の高値、安値、推移の概要Shaperon過去の株価現在の株価₩503.0052週高値₩3,390.0052週安値₩498.00ベータ0.341ヶ月の変化-48.25%3ヶ月変化-70.58%1年変化-83.48%3年間の変化-87.79%5年間の変化n/aIPOからの変化-94.17%最新ニュースNew Risk • Jun 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩281m revenue, or US$182k). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (₩35.1b market cap, or US$22.7m).お知らせ • Apr 17Shaperon Inc. announced that it has received KRW 8.6 billion in fundingOn April 15, 2026, Shaperon Inc. has closed the transaction.お知らせ • Apr 09Shaperon Inc. announced that it expects to receive KRW 8.6 billion in fundingShaperon Inc. announces a private placement to issue Series 1 Bearer-type interest-bearing unsecured private placement convertible bonds for gross proceeds of KRW 8,600,000,000 on April 7, 2026. Expected closing date of the offering is April 15, 2026. Interest rate of the Notes is 0% and Maturity of the Bonds is April 15, 2031. Conversion price is KRW 1,685. Conversion period starts from April 15, 2027 and ends on March 15, 2031. GVA Coven-14 General Private Investment Trust advised by Samsung Securities Co., Ltd. for KRW 800,000,000, GVA Coven-0 General Private Investment Trust advised by Samsung Securities Co., Ltd for KRW 750,000,000.お知らせ • Mar 12Shaperon Inc., Annual General Meeting, Mar 27, 2026Shaperon Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 174-10, jagok-ro, gangnam-gu, seoul South KoreaNew Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 87% over the past year. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩12m revenue, or US$8.0k). Minor Risk Market cap is less than US$100m (₩80.1b market cap, or US$54.5m).お知らせ • Nov 14Shaperon Inc. Attends 7th Inflammasome Therapeutics Summit in BostonShaperon Inc. announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company's latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. The Inflammaome Therapeutics Summit is a leading global conference dedicated to advances in inflammasome research and drug development. Shaperon's participation and keynote presentation underscore the growing recognition of its GPCR19-based drug discovery platform as an emerging technology with the potential to reshape the treatment landscape for inflammatory and autoimmune diseases. In his keynote, Dr. Seong presented the company's progress on GPCR19-targeted inflammasome modulation, a novel therapeutic strategy designed to control inflammation at its upstream initiation phase. Unlike conventionalNLRP3 inhibitors that act downstream, Shaperon's approach regulates the formation of the inflammasome complex itself, confirming the broad applicability of its inflammasome-targeted technology. Shaperon's topical candidate NuGel, the world's first GPCR19 agonist for atopic dermatitis, demonstrated positive efficacy and safety results in Phase 2b Part 1 clinical trials. The company also shared new preclinical data across acne, rosacea, and diabetic foot ulcers, confirming the broad applicabilityof its inflammasome- target technology. Shaperon's proprietary AI-powered drug discovery platform integrates multi-parametric modeling to predict target suitability, pharmacokinetic properties and toxicity profiles, enabling faster and more reliable development decisions. One of its AI-derived candidates, Nualeratine, showed a 74% higher hair regrowth rate in preclinical models of autoimmune alopecia compared to competing compounds.最新情報をもっと見るRecent updatesNew Risk • Jun 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩281m revenue, or US$182k). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (₩35.1b market cap, or US$22.7m).お知らせ • Apr 17Shaperon Inc. announced that it has received KRW 8.6 billion in fundingOn April 15, 2026, Shaperon Inc. has closed the transaction.お知らせ • Apr 09Shaperon Inc. announced that it expects to receive KRW 8.6 billion in fundingShaperon Inc. announces a private placement to issue Series 1 Bearer-type interest-bearing unsecured private placement convertible bonds for gross proceeds of KRW 8,600,000,000 on April 7, 2026. Expected closing date of the offering is April 15, 2026. Interest rate of the Notes is 0% and Maturity of the Bonds is April 15, 2031. Conversion price is KRW 1,685. Conversion period starts from April 15, 2027 and ends on March 15, 2031. GVA Coven-14 General Private Investment Trust advised by Samsung Securities Co., Ltd. for KRW 800,000,000, GVA Coven-0 General Private Investment Trust advised by Samsung Securities Co., Ltd for KRW 750,000,000.お知らせ • Mar 12Shaperon Inc., Annual General Meeting, Mar 27, 2026Shaperon Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 174-10, jagok-ro, gangnam-gu, seoul South KoreaNew Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 87% over the past year. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩12m revenue, or US$8.0k). Minor Risk Market cap is less than US$100m (₩80.1b market cap, or US$54.5m).お知らせ • Nov 14Shaperon Inc. Attends 7th Inflammasome Therapeutics Summit in BostonShaperon Inc. announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company's latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. The Inflammaome Therapeutics Summit is a leading global conference dedicated to advances in inflammasome research and drug development. Shaperon's participation and keynote presentation underscore the growing recognition of its GPCR19-based drug discovery platform as an emerging technology with the potential to reshape the treatment landscape for inflammatory and autoimmune diseases. In his keynote, Dr. Seong presented the company's progress on GPCR19-targeted inflammasome modulation, a novel therapeutic strategy designed to control inflammation at its upstream initiation phase. Unlike conventionalNLRP3 inhibitors that act downstream, Shaperon's approach regulates the formation of the inflammasome complex itself, confirming the broad applicability of its inflammasome-targeted technology. Shaperon's topical candidate NuGel, the world's first GPCR19 agonist for atopic dermatitis, demonstrated positive efficacy and safety results in Phase 2b Part 1 clinical trials. The company also shared new preclinical data across acne, rosacea, and diabetic foot ulcers, confirming the broad applicabilityof its inflammasome- target technology. Shaperon's proprietary AI-powered drug discovery platform integrates multi-parametric modeling to predict target suitability, pharmacokinetic properties and toxicity profiles, enabling faster and more reliable development decisions. One of its AI-derived candidates, Nualeratine, showed a 74% higher hair regrowth rate in preclinical models of autoimmune alopecia compared to competing compounds.お知らせ • Nov 06Shaperon Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.860387 billion.Shaperon Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.860387 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,049,314 Price\Range: KRW 1549 Discount Per Security: KRW 30.98 Transaction Features: Rights Offeringお知らせ • Aug 19Shaperon Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.0426 billion.Shaperon Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.0426 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,100,000 Price\Range: KRW 1866 Discount Per Security: KRW 37.32 Transaction Features: Rights OfferingNew Risk • Aug 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩16b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 86% over the past year. Revenue is less than US$1m (₩30m revenue, or US$21k). Minor Risk Market cap is less than US$100m (₩60.9b market cap, or US$43.8m).分析記事 • Aug 01Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • May 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Revenue has declined by 92% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩18m revenue, or US$13k). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩114.4b market cap, or US$82.9m).New Risk • Mar 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩17b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 92% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩18m revenue, or US$12k). Minor Risk Market cap is less than US$100m (₩97.1b market cap, or US$66.3m).New Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 36% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩91m revenue, or US$63k). Minor Risk Market cap is less than US$100m (₩101.4b market cap, or US$70.0m).お知らせ • Mar 06Shaperon Inc., Annual General Meeting, Mar 25, 2025Shaperon Inc., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 419, bongeunsa-ro, gangnam-gu, seoul South KoreaNew Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue has declined by 36% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩91m revenue, or US$63k). Minor Risk Market cap is less than US$100m (₩121.3b market cap, or US$83.2m).分析記事 • Dec 20Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Sep 02We're Keeping An Eye On Shaperon's (KOSDAQ:378800) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...New Risk • Jul 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 31% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue has declined by 84% over the past year. Revenue is less than US$1m (₩215m revenue, or US$156k). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (₩45.3b market cap, or US$32.9m).New Risk • May 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 84% over the past year. Revenue is less than US$1m (₩215m revenue, or US$158k). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩52.8b market cap, or US$38.7m).分析記事 • Apr 12Is Shaperon (KOSDAQ:378800) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...New Risk • Apr 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 89% over the past year. Revenue is less than US$1m (₩215m revenue, or US$156k). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩66.6b market cap, or US$48.2m).お知らせ • Mar 20Shaperon Enrolls its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy 'Nugel'Shaperon Inc. announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis. This milestone marks the start of a crucial phase in Shaperon's effort to advance treatment for patients globally. With FDA approval secured for the Global Phase 2 Clinical Trials (IND) of Nugel in September 2023, Shaperon is dedicated to evaluating its efficacy in improving the Eczema Area Severity Index (EASI) across a diverse cohort of 210 patients with mild to moderate atopic dermatitis. Employing a rigorous double-blind, placebo-controlled methodology, the trial is anticipated to conclude by the first half of 2026. Market research forecasts indicate a robust growth of over 8.7%, projecting the global atopic dermatitis market to reach $19.1 billion by 2030. Presently, patients rely on steroids and FDA-approved medications, yet there remains a pressing need for novel drugs due to their adverse effects and limited efficacy. Of particular note, more than 70% of patients exhibit positive responses to the biomarker discovered during Shaperon's phase 2 clinical trials in Korea, categorized as "A type A atopic patients." This treatment, distinguished by its superior safety and efficacy compared to existing JAK inhibitors or PDE4 inhibitors in the market, has garnered attention at U.S. and European forums. Shaperon has already initiated patent applications for this biomarker, enabling tailored treatments for patients showing exceptional responses to Nugel. Nugel represents a paradigm shift in atopic dermatitis therapy as the world's first inflammation control drug targeting 'GPCR19' action. Its unique mechanism of action, exclusive to immune-related cells, offers minimal side effects while effectively addressing inflammatory pathways. Beyond atopic dermatitis, Nugel holds promise for treating a spectrum of skin conditions, further underscoring its potential impact on global healthcare.New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩114.7b market cap, or US$89.5m).株主還元A378800KR BiotechsKR 市場7D-7.4%-2.7%-9.7%1Y-83.5%2.4%131.3%株主還元を見る業界別リターン: A378800過去 1 年間で2.4 % の収益を上げたKR Biotechs業界を下回りました。リターン対市場: A378800は、過去 1 年間で131.3 % のリターンを上げたKR市場を下回りました。価格変動Is A378800's price volatile compared to industry and market?A378800 volatilityA378800 Average Weekly Movement17.5%Biotechs Industry Average Movement11.0%Market Average Movement9.3%10% most volatile stocks in KR Market16.7%10% least volatile stocks in KR Market4.9%安定した株価: A378800の株価は、 KR市場と比較して過去 3 か月間で変動しています。時間の経過による変動: A378800の weekly volatility ( 18% ) は過去 1 年間安定していますが、依然としてKRの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200853Seung-Yong Seongwww.shaperon.com臨床段階のバイオテクノロジー企業であるシャペロン社は、アンメット・メディカル・ニーズの高い免疫介在性炎症性疾患を標的とした新規のインフラマソーム阻害剤とナノボディ治療薬を開発している。同社は、第2相臨床試験中のジェルタイプのアトピー性皮膚炎治療薬候補であるNuGelと、全身性炎症反応症候群の治療薬として第2相臨床試験中のHY209の静脈注射剤であるNuSepinを提供している。また、神経炎症性疾患の治療に用いるHY209の経口製剤である経口HY209、慢性炎症の治療に用いるHY209類似体も提供している。さらに、PD-L1とCD47を標的とする二重特異性ナノボディであり、自然免疫と適応免疫の両方を標的とする新規免疫療法であるパピリキシマブ、SARS-CoV-2に対する単一ドメイン中和抗体であるサビキシマブ、がん領域での使用を目的とした未発表のナノボディ製品候補も提供している。同社は2008年に設立され、韓国のソウルに本社を置いている。もっと見るShaperon Inc. 基礎のまとめShaperon の収益と売上を時価総額と比較するとどうか。A378800 基礎統計学時価総額₩24.32b収益（TTM）-₩15.54b売上高(TTM)₩281.40m82.7xP/Sレシオ-1.5xPER（株価収益率A378800 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A378800 損益計算書（TTM）収益₩281.40m売上原価₩394.61m売上総利益-₩113.21mその他の費用₩15.43b収益-₩15.54b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-336.12グロス・マージン-40.23%純利益率-5,523.53%有利子負債／自己資本比率0%A378800 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/08 12:52終値2026/07/08 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Shaperon Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩281m revenue, or US$182k). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (₩35.1b market cap, or US$22.7m).
お知らせ • Apr 17Shaperon Inc. announced that it has received KRW 8.6 billion in fundingOn April 15, 2026, Shaperon Inc. has closed the transaction.
お知らせ • Apr 09Shaperon Inc. announced that it expects to receive KRW 8.6 billion in fundingShaperon Inc. announces a private placement to issue Series 1 Bearer-type interest-bearing unsecured private placement convertible bonds for gross proceeds of KRW 8,600,000,000 on April 7, 2026. Expected closing date of the offering is April 15, 2026. Interest rate of the Notes is 0% and Maturity of the Bonds is April 15, 2031. Conversion price is KRW 1,685. Conversion period starts from April 15, 2027 and ends on March 15, 2031. GVA Coven-14 General Private Investment Trust advised by Samsung Securities Co., Ltd. for KRW 800,000,000, GVA Coven-0 General Private Investment Trust advised by Samsung Securities Co., Ltd for KRW 750,000,000.
お知らせ • Mar 12Shaperon Inc., Annual General Meeting, Mar 27, 2026Shaperon Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 174-10, jagok-ro, gangnam-gu, seoul South Korea
New Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 87% over the past year. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩12m revenue, or US$8.0k). Minor Risk Market cap is less than US$100m (₩80.1b market cap, or US$54.5m).
お知らせ • Nov 14Shaperon Inc. Attends 7th Inflammasome Therapeutics Summit in BostonShaperon Inc. announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company's latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. The Inflammaome Therapeutics Summit is a leading global conference dedicated to advances in inflammasome research and drug development. Shaperon's participation and keynote presentation underscore the growing recognition of its GPCR19-based drug discovery platform as an emerging technology with the potential to reshape the treatment landscape for inflammatory and autoimmune diseases. In his keynote, Dr. Seong presented the company's progress on GPCR19-targeted inflammasome modulation, a novel therapeutic strategy designed to control inflammation at its upstream initiation phase. Unlike conventionalNLRP3 inhibitors that act downstream, Shaperon's approach regulates the formation of the inflammasome complex itself, confirming the broad applicability of its inflammasome-targeted technology. Shaperon's topical candidate NuGel, the world's first GPCR19 agonist for atopic dermatitis, demonstrated positive efficacy and safety results in Phase 2b Part 1 clinical trials. The company also shared new preclinical data across acne, rosacea, and diabetic foot ulcers, confirming the broad applicabilityof its inflammasome- target technology. Shaperon's proprietary AI-powered drug discovery platform integrates multi-parametric modeling to predict target suitability, pharmacokinetic properties and toxicity profiles, enabling faster and more reliable development decisions. One of its AI-derived candidates, Nualeratine, showed a 74% higher hair regrowth rate in preclinical models of autoimmune alopecia compared to competing compounds.
New Risk • Jun 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩281m revenue, or US$182k). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (₩35.1b market cap, or US$22.7m).
お知らせ • Apr 17Shaperon Inc. announced that it has received KRW 8.6 billion in fundingOn April 15, 2026, Shaperon Inc. has closed the transaction.
お知らせ • Apr 09Shaperon Inc. announced that it expects to receive KRW 8.6 billion in fundingShaperon Inc. announces a private placement to issue Series 1 Bearer-type interest-bearing unsecured private placement convertible bonds for gross proceeds of KRW 8,600,000,000 on April 7, 2026. Expected closing date of the offering is April 15, 2026. Interest rate of the Notes is 0% and Maturity of the Bonds is April 15, 2031. Conversion price is KRW 1,685. Conversion period starts from April 15, 2027 and ends on March 15, 2031. GVA Coven-14 General Private Investment Trust advised by Samsung Securities Co., Ltd. for KRW 800,000,000, GVA Coven-0 General Private Investment Trust advised by Samsung Securities Co., Ltd for KRW 750,000,000.
お知らせ • Mar 12Shaperon Inc., Annual General Meeting, Mar 27, 2026Shaperon Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 174-10, jagok-ro, gangnam-gu, seoul South Korea
New Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 87% over the past year. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩12m revenue, or US$8.0k). Minor Risk Market cap is less than US$100m (₩80.1b market cap, or US$54.5m).
お知らせ • Nov 14Shaperon Inc. Attends 7th Inflammasome Therapeutics Summit in BostonShaperon Inc. announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company's latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. The Inflammaome Therapeutics Summit is a leading global conference dedicated to advances in inflammasome research and drug development. Shaperon's participation and keynote presentation underscore the growing recognition of its GPCR19-based drug discovery platform as an emerging technology with the potential to reshape the treatment landscape for inflammatory and autoimmune diseases. In his keynote, Dr. Seong presented the company's progress on GPCR19-targeted inflammasome modulation, a novel therapeutic strategy designed to control inflammation at its upstream initiation phase. Unlike conventionalNLRP3 inhibitors that act downstream, Shaperon's approach regulates the formation of the inflammasome complex itself, confirming the broad applicability of its inflammasome-targeted technology. Shaperon's topical candidate NuGel, the world's first GPCR19 agonist for atopic dermatitis, demonstrated positive efficacy and safety results in Phase 2b Part 1 clinical trials. The company also shared new preclinical data across acne, rosacea, and diabetic foot ulcers, confirming the broad applicabilityof its inflammasome- target technology. Shaperon's proprietary AI-powered drug discovery platform integrates multi-parametric modeling to predict target suitability, pharmacokinetic properties and toxicity profiles, enabling faster and more reliable development decisions. One of its AI-derived candidates, Nualeratine, showed a 74% higher hair regrowth rate in preclinical models of autoimmune alopecia compared to competing compounds.
お知らせ • Nov 06Shaperon Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.860387 billion.Shaperon Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.860387 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,049,314 Price\Range: KRW 1549 Discount Per Security: KRW 30.98 Transaction Features: Rights Offering
お知らせ • Aug 19Shaperon Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.0426 billion.Shaperon Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.0426 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,100,000 Price\Range: KRW 1866 Discount Per Security: KRW 37.32 Transaction Features: Rights Offering
New Risk • Aug 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩16b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 86% over the past year. Revenue is less than US$1m (₩30m revenue, or US$21k). Minor Risk Market cap is less than US$100m (₩60.9b market cap, or US$43.8m).
分析記事 • Aug 01Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • May 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Revenue has declined by 92% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩18m revenue, or US$13k). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩114.4b market cap, or US$82.9m).
New Risk • Mar 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩17b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 92% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩18m revenue, or US$12k). Minor Risk Market cap is less than US$100m (₩97.1b market cap, or US$66.3m).
New Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 36% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩91m revenue, or US$63k). Minor Risk Market cap is less than US$100m (₩101.4b market cap, or US$70.0m).
お知らせ • Mar 06Shaperon Inc., Annual General Meeting, Mar 25, 2025Shaperon Inc., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 419, bongeunsa-ro, gangnam-gu, seoul South Korea
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue has declined by 36% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩91m revenue, or US$63k). Minor Risk Market cap is less than US$100m (₩121.3b market cap, or US$83.2m).
分析記事 • Dec 20Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Sep 02We're Keeping An Eye On Shaperon's (KOSDAQ:378800) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
New Risk • Jul 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 31% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue has declined by 84% over the past year. Revenue is less than US$1m (₩215m revenue, or US$156k). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (₩45.3b market cap, or US$32.9m).
New Risk • May 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 84% over the past year. Revenue is less than US$1m (₩215m revenue, or US$158k). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩52.8b market cap, or US$38.7m).
分析記事 • Apr 12Is Shaperon (KOSDAQ:378800) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
New Risk • Apr 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 89% over the past year. Revenue is less than US$1m (₩215m revenue, or US$156k). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩66.6b market cap, or US$48.2m).
お知らせ • Mar 20Shaperon Enrolls its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy 'Nugel'Shaperon Inc. announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis. This milestone marks the start of a crucial phase in Shaperon's effort to advance treatment for patients globally. With FDA approval secured for the Global Phase 2 Clinical Trials (IND) of Nugel in September 2023, Shaperon is dedicated to evaluating its efficacy in improving the Eczema Area Severity Index (EASI) across a diverse cohort of 210 patients with mild to moderate atopic dermatitis. Employing a rigorous double-blind, placebo-controlled methodology, the trial is anticipated to conclude by the first half of 2026. Market research forecasts indicate a robust growth of over 8.7%, projecting the global atopic dermatitis market to reach $19.1 billion by 2030. Presently, patients rely on steroids and FDA-approved medications, yet there remains a pressing need for novel drugs due to their adverse effects and limited efficacy. Of particular note, more than 70% of patients exhibit positive responses to the biomarker discovered during Shaperon's phase 2 clinical trials in Korea, categorized as "A type A atopic patients." This treatment, distinguished by its superior safety and efficacy compared to existing JAK inhibitors or PDE4 inhibitors in the market, has garnered attention at U.S. and European forums. Shaperon has already initiated patent applications for this biomarker, enabling tailored treatments for patients showing exceptional responses to Nugel. Nugel represents a paradigm shift in atopic dermatitis therapy as the world's first inflammation control drug targeting 'GPCR19' action. Its unique mechanism of action, exclusive to immune-related cells, offers minimal side effects while effectively addressing inflammatory pathways. Beyond atopic dermatitis, Nugel holds promise for treating a spectrum of skin conditions, further underscoring its potential impact on global healthcare.
New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩114.7b market cap, or US$89.5m).
